A Study of Efonidipine Hydrochloride Ethanolate 20 mg and Telmisartan 40 mg Tablets Versus Efonidipine Hydrochloride Ethanolate Tablets 20 mg and Telmisartan Tablets 40 mg as a single drug in a patient for the treatment of Hypertension.
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2018/12/016607
- Lead Sponsor
- Ajanta Pharma Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 244
Subjects meeting all of the following criteria will be recruited for the trial:
1.Male or Female subjects between 18 to 65 years of age (Both Inclusive).
2.Treatment-Naïve subjects who are suffering from Stage 2 Hypertension.
3.Subjects diagnosed with mean SBP of >=160 to <=180 mmHg and mean DBP >=100 to <=110 mmHg (3 readings will be taken by validated automated blood pressure machine in sitting position, first reading will be taken after 15 min. rest and subsequent two readings will be recorded at the interval of 2 min. each).
4.Subjects who are willing to sign informed consent for participation in the study and willing to adhere to all protocol procedures.
Subjects will be excluded if ANY of the following conditions apply:
1.Suspected hypersensitivity to any of the ingredients of study medication.
2.Subjects with known case of Secondary or Malignant Hypertension.
3.Subjects with abnormal Renal Function Test.
4.Subjects with abnormal eGFR less than 60 mL/min/1.73 m2 will be excluded from the study.
5.Subjects with known case of bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, post-renal transplant or with only one functioning kidney.
6.Subjects with hyponatremia as per blood biochemistry results at screening.
7.Subjects with Serum potassium more than 5.5 mEq/L or less than 3.5 mEq/L at baseline.
8.Subjects with abnormal Liver Function Tests.
9.Subjects with abnormal Thyroid Function Test.
10.Subjects with known case of Type 1 Diabetes will be excluded from the study.
11.Subjects with Type 2 Diabetes Mellitus whose diabetes has not been stable and uncontrolled for the previous three months and with HbA1c value greater than 8% will be excluded from the study.
12.Subjects with known case of symptomatic congestive heart failure, severe aortic stenosis, unstable angina pectoris, myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery, sinus node dysfunction and any clinically significant cardiac arrhythmias will be excluded from the study.
13.Subjects with known case of Stroke will be excluded from the study.
14.Subjects diagnosed or suffering from any Oncological Conditions since last 2 years will be excluded from the study.
15.Subjects with known case of Epileptic seizures will be excluded from the study.
16.Subjects with clinical history of bipolar disorder i.e. who are taking lithium.
17.Female subjects who are pregnant or lactating or planning to become pregnant during the study period. Females who are not ready to use acceptable contraceptive methods during the course of study.
18.Concurrent participation in another clinical trial or any investigational therapy within 30 days prior to signing informed consent.
19.Currently taking prohibited concomitant medications(s) listed and inability/unwillingness to discontinue them for the entire study period.
20.Suspected inability or unwillingness to comply with the study procedures.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method